Cargando…

From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain

PURPOSE: Quadrivalent influenza vaccine (QIV) includes the same strains as trivalent influenza vaccine (TIV) plus an additional B strain of the other B lineage. The aim of the study was to analyse the public health and economic impact of replacing TIV with QIV in different scenarios in Spain. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crépey, Pascal, Redondo, Esther, Díez-Domingo, Javier, Ortiz de Lejarazu, Raúl, Martinón-Torres, Federico, Gil de Miguel, Ángel, López-Belmonte, Juan Luis, Alvarez, Fabián P., Bricout, Hélène, Solozabal, Míriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241783/ https://www.ncbi.nlm.nih.gov/pubmed/32437476 http://dx.doi.org/10.1371/journal.pone.0233526

Ejemplares similares

Clinical and economic burden of physician-diagnosed influenza in adults during the 2017/2018 epidemic season in Spain
por: Gil-de-Miguel, Ángel, et al.
Publicado: (2022)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Excess hospitalizations and mortality associated with seasonal influenza in Spain, 2008–2018
por: Pumarola, T., et al.
Publicado: (2023)

Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad
por: de Miguel, Ángel Gil, et al.
Publicado: (2020)

Vacuna antigripal trivalente de alta dosis: seguridad e inmunogenicidad
por: de Lejarazu, Raúl Ortiz, et al.
Publicado: (2020)

Addressing influenza’s underestimated burden – Iberian experts call to action
por: Gil-de-Miguel, Ángel, et al.
Publicado: (2023)

A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom
por: Rigoine de Fougerolles, Thierry, et al.
Publicado: (2021)

Retrospective public health impact of a quadrivalent influenza vaccine in the United States
por: Crépey, Pascal, et al.
Publicado: (2015)

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2019)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010‐2016
por: Oliva, Jesús, et al.
Publicado: (2017)

Descripción de la gripe B en las epidemias estacionales de España
por: Ortiz de Lejarazu, Raúl, et al.
Publicado: (2018)

A tool for early estimation of influenza vaccination coverage in Spanish general population and healthcare workers in the 2018–19 season: the Gripómetro
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2018)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
por: Bianculli, Pablo Manuel, et al.
Publicado: (2022)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2022)

Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model
por: Crépey, Pascal, et al.
Publicado: (2020)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
por: You, Joyce HS, et al.
Publicado: (2014)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study
por: Milne, George J., et al.
Publicado: (2016)

Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study
por: Martinón-Torres, F., et al.
Publicado: (2022)

Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil – comparison of outcomes from different static model types
por: Van Bellinghen, Laure-Anne, et al.
Publicado: (2018)

Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015–2018
por: Martinón-Torres, F., et al.
Publicado: (2023)

Influenza B Lineages Have More in Common Than Meets the Eye. Trivalent Influenza Vaccines Trigger Heterotypic Antibodies Against Both Influenza B Viruses
por: Sánchez-de Prada, Laura, et al.
Publicado: (2021)

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2023)

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
por: Dolk, Christiaan, et al.
Publicado: (2016)

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
por: Kim, Yun-Kyung, et al.
Publicado: (2018)

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017
por: Gaglani, Manjusha, et al.
Publicado: (2020)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
por: Arbo, Antonio, et al.
Publicado: (2022)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Economic Burden of Contraception Management in Spain
por: Parra Ribes, Inmaculada, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lmon77ti6jgdegriu416m3ft2e